Vor Biopharma is a technology company.
Vor Biopharma has raised $152.0M across 2 funding rounds.
Vor Biopharma has raised $152.0M in total across 2 funding rounds.
Vor Biopharma has raised $152.0M in total across 2 funding rounds.
Vor Biopharma's investors include 5AM Ventures, Carol Gallagher, Robert Garland, Nextech Invest, OrbiMed, Osage University Partners, The Column Group.
Vor Biopharma (Vor Bio) is a clinical-stage biotechnology company developing targeted therapies for autoimmune diseases, with its lead program telitacicept, a dual BAFF/APRIL inhibitor designed to silence survival signals for harmful B cells, halting autoantibody production and downstream tissue damage.[1][2] The company serves patients with autoimmune conditions by addressing upstream drivers of disease rather than just symptoms, aiming for durable, disease-modifying benefits across multiple indications; its mission is to restore immune system balance and improve lives, with a vision to lead globally in autoimmune therapeutics.[1][2] Growth momentum stems from a seasoned team advancing telitacicept toward commercialization, backed by expertise in biologics and recent leadership hires from firms like Sarepta Therapeutics, where net product revenue hit $1.8 billion in 2024.[1]
Vor Bio emerged from a team of biopharma veterans specializing in autoimmune disease, biologics development, and commercialization, though specific founding year and founders are not detailed in available sources.[1] The idea crystallized around challenging conventional symptom-focused treatments by targeting root causes like B-cell survival signals, leading to telitacicept as the flagship program.[1][2] Pivotal momentum includes assembling a "proven team built to win," with recent additions like an Executive Vice President from Sarepta—who oversaw launches of RNA and gene therapies for Duchenne muscular dystrophy—accelerating the path to novel therapies.[1]
Vor Bio rides the autoimmune therapy revolution, shifting from lifelong symptom management to root-cause interventions amid rising demand for biologics that offer remission-like outcomes.[1][2] Timing aligns with advances in B-cell targeting (e.g., BAFF/APRIL pathways validated in diseases like lupus and rheumatoid arthritis), fueled by market forces like aging populations, diagnostic improvements, and post-pandemic autoimmune spikes. By influencing the ecosystem through partnerships and a high-caliber team, Vor accelerates innovation, potentially setting standards for next-gen immunomodulators in a $100B+ biologics market.[1]
Vor Bio's trajectory hinges on telitacicept's clinical readout and regulatory milestones, with commercialization expertise positioning it for rapid market entry if data confirms best-in-class profile.[1] Trends like precision immunology and combo therapies will shape its path, expanding to new indications while navigating competition from big pharma. Its influence could evolve from challenger to leader, transforming autoimmune care—echoing its opening charge in silencing disease at the source for patients worldwide.[1][2]
Vor Biopharma has raised $152.0M across 2 funding rounds. Most recently, it raised $110.0M Series B in July 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 1, 2020 | $110.0M Series B | 5AM Ventures, Carol Gallagher, Robert Garland, Nextech Invest, OrbiMed, Osage University Partners, The Column Group | |
| Feb 1, 2019 | $42.0M Series A | 5AM Ventures, Carol Gallagher, Robert Garland, Nextech Invest, OrbiMed, Osage University Partners, The Column Group |